Valeant Pharmaceuticals Intl Company Profile (TSE:VRX)

About Valeant Pharmaceuticals Intl (TSE:VRX)

Valeant Pharmaceuticals Intl logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: TSE:VRX
  • CUSIP: N/A
  • Web: www.valeant.com/
Capitalization:
  • Market Cap: C$5.89 billion
  • Outstanding Shares: 348,521,000
Average Prices:
  • 50 Day Moving Avg: C$17.69
  • 200 Day Moving Avg: C$17.15
  • 52 Week Range: C$11.20 - C$36.65
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: -0.33
Sales & Book Value:
  • Annual Revenue: C$9.22 billion
  • Price / Sales: 0.64
  • Book Value: C$11.28 per share
  • Price / Book: 1.50
Profitability:
  • EBIDTA: C$3.75 billion
  • Net Margins: -1.66%
  • Return on Equity: -3.90%
  • Return on Assets: -0.35%
Misc:
  • Average Volume: 1.42 million shs.
  • Short Ratio: 11.1
 

Frequently Asked Questions for Valeant Pharmaceuticals Intl (TSE:VRX)

What is Valeant Pharmaceuticals Intl's stock symbol?

Valeant Pharmaceuticals Intl trades on the Tornton Stock Exchange (TSX) under the ticker symbol "VRX."

When will Valeant Pharmaceuticals Intl make its next earnings announcement?

Valeant Pharmaceuticals Intl is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Valeant Pharmaceuticals Intl.

Where is Valeant Pharmaceuticals Intl's stock going? Where will Valeant Pharmaceuticals Intl's stock price be in 2017?

5 brokerages have issued 1 year price objectives for Valeant Pharmaceuticals Intl's stock. Their forecasts range from C$19.00 to C$26.00. On average, they anticipate Valeant Pharmaceuticals Intl's stock price to reach C$23.33 in the next year. View Analyst Ratings for Valeant Pharmaceuticals Intl.

Who are some of Valeant Pharmaceuticals Intl's key competitors?

Who are Valeant Pharmaceuticals Intl's key executives?

Valeant Pharmaceuticals Intl's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Director
  • D. Robert Hale, Independent Director
  • Argeris N. Karabelas Ph.D., Independent Director

How do I buy Valeant Pharmaceuticals Intl stock?

Shares of Valeant Pharmaceuticals Intl and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Valeant Pharmaceuticals Intl's stock price today?

One share of Valeant Pharmaceuticals Intl stock can currently be purchased for approximately C$16.90.


MarketBeat Community Rating for Valeant Pharmaceuticals Intl (TSE VRX)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  358
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals Intl (TSE:VRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: C$23.33

Analysts' Ratings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Show:
DateFirmActionRatingPrice TargetDetails
7/12/2017TD SecuritiesBoost Price TargetHoldC$26.00View Rating Details
6/29/2017Cantor FitzgeraldReiterated RatingOverweightView Rating Details
6/19/2017Royal Bank of CanadaReiterated RatingSector PerformC$25.00View Rating Details
5/10/2017ScotiabankBoost Price TargetSector PerformC$19.00View Rating Details
12/15/2016Morgan StanleyDowngradeOverweight -> Equal WeightView Rating Details
11/19/2015Citigroup Inc.Reiterated RatingOverweightView Rating Details
11/2/2015Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Valeant Pharmaceuticals Intl (TSE:VRX)
Earnings by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Earnings History by Quarter for Valeant Pharmaceuticals Intl (TSE VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017        
5/8/2014C$1.83C$1.90C$2.05 billionViewN/AView Earnings Details
8/7/20132Q13C$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals Intl (TSE:VRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171$1.05$1.05$1.05
Q4 20171$1.01$1.01$1.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals Intl (TSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals Intl (TSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals Intl (TSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Schutter Richard Urbain DeDirectorBuy4,900C$14.35C$70,315.00
8/9/2017John PaulsonDirectorSell24,700C$14.66C$362,102.00
5/11/2017Schutter Richard Urbain DeDirectorBuy20,000C$13.90C$278,000.00
3/15/2017Schutter Richard Urbain DeDirectorBuy10,000C$10.80C$108,000.00
11/5/2015J. Michael PearsonDirectorSell350,000C$0.00C$0.00
10/21/2015Ron FarmerDirectorBuy1,000C$193.00C$193,000.00
5/26/2015Whitaker AnneInsiderBuy2,500C$234.00C$585,000.00
5/4/2015Robert Roswell Chai-OnnInsiderSell90,938C$222.54C$20,237,433.46
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Valeant Pharmaceuticals Intl (TSE:VRX)
Latest Headlines for Valeant Pharmaceuticals Intl (TSE:VRX)
Source:
DateHeadline
benzinga.com logoGlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors - Benzinga
www.benzinga.com - September 19 at 3:27 PM
benzinga.com logoWhat You Should Know About The Drug Approval Valeant Could Receive This Week - Benzinga
www.benzinga.com - September 19 at 9:26 AM
finance.yahoo.com logoValeant To Participate At The Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 7:54 AM
finance.yahoo.com logoValeant Commits $200,000 to Support Hurricane Relief Efforts
finance.yahoo.com - September 15 at 11:15 AM
seekingalpha.com logoHas Valeant Run Out Of Catalysts? - Seeking Alpha
seekingalpha.com - September 13 at 11:07 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is STILL Too Ugly to Buy - Investorplace.com
investorplace.com - September 13 at 11:07 AM
nasdaq.com logoValeant Pharmaceuticals International Breaks Above 200-Day Moving Average - Bullish for VRX
www.nasdaq.com - September 12 at 12:01 PM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 10 at 2:42 AM
finance.yahoo.com logoFollow the Crucial '$20 Level Rule' When Trading Stocks
finance.yahoo.com - September 9 at 9:48 AM
seekingalpha.com logoValeant: This just got unreasonable - Seeking Alpha
seekingalpha.com - September 6 at 10:04 AM
finance.yahoo.com logoOrtho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
finance.yahoo.com - September 6 at 10:04 AM
finance.yahoo.com logoValeant To Participate At The Morgan Stanley Global Healthcare Conference
finance.yahoo.com - September 6 at 10:04 AM
finance.yahoo.com logoDaily Coverage on Healthcare Stocks, Valeant Pharma International, Nuvo Pharma, Knight Therapeutics, and Acerus Pharma
finance.yahoo.com - September 6 at 10:04 AM
seekingalpha.com logoValeant: A Clear Sell - Seeking Alpha
seekingalpha.com - September 3 at 8:04 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Will Be Just Fine ... - Investorplace.com
investorplace.com - September 3 at 8:04 AM
msn.com logoBetter Turnaround Play: Bombardier, Inc. vs. Valeant Pharmaceuticals Intl Inc.
www.msn.com - September 2 at 10:18 AM
finance.yahoo.com logoWilmington company sues former partner following work for Salix, Valeant
finance.yahoo.com - September 1 at 10:54 AM
finance.yahoo.com logoThe Simple Reason I Won't Buy Intrexon
finance.yahoo.com - September 1 at 10:54 AM
seekingalpha.com logoValeant: Headline Risk Vs. Fundamentals - Seeking Alpha
seekingalpha.com - August 30 at 10:56 AM
finance.yahoo.com logoValeant Pharmaceuticals: Weakness, Weakness Everywhere?
finance.yahoo.com - August 30 at 10:56 AM
finance.yahoo.com logoWhy Did Valeant Pharmaceuticals (VRX) Stock Fall Today?
finance.yahoo.com - August 30 at 10:56 AM
finance.yahoo.com logoValeant: No Fundamental Reasons for Today's Selloff?
finance.yahoo.com - August 30 at 10:56 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Falls on New Legal Battle - Investorplace.com
investorplace.com - August 29 at 9:31 AM
investorplace.com logoIs the Valeant Pharmaceuticals Intl Inc (VRX) Debt Situation Overblown? - Investorplace.com
investorplace.com - August 25 at 3:34 PM
finance.yahoo.com logoHere's the Simple Issue I Still Have With Valeant Pharmaceuticals (and Why You Shouldn't Buy)
finance.yahoo.com - August 25 at 12:26 PM
finance.yahoo.com logoValeant’s Latest Legal Threat Could Be Especially Costly
finance.yahoo.com - August 25 at 12:26 PM
finance.yahoo.com logoValeant: The Long or Short of It
finance.yahoo.com - August 25 at 12:26 PM
finance.yahoo.com logoValeant's Legal Bills Are Piling Up Following Latest Securities Fraud Lawsuit
finance.yahoo.com - August 25 at 12:26 PM
americanbankingnews.com logoSchutter Richard Urbain De Purchases 4,900 Shares of Valeant Pharmaceuticals Intl Inc (VRX) Stock
www.americanbankingnews.com - August 24 at 10:34 PM
seekingalpha.com logoValeant Looks Good Post-Q2 - Seeking Alpha
seekingalpha.com - August 23 at 11:45 PM
benzinga.com logoWhat's The FDA Saying About Valeant (NYSE: VRX)'s ... - Benzinga - Benzinga
www.benzinga.com - August 23 at 1:41 PM
investorplace.com logoWhy Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Higher Today - Investorplace.com
investorplace.com - August 19 at 8:54 AM
investorplace.com logoValeant Pharmaceuticals Intl Inc (VRX) Stock Is a Gamble You Can Win - Investorplace.com
investorplace.com - August 19 at 8:54 AM
prnewswire.com logoValeant Receives FDA Confirmation Of Voluntary Action Indicated (VAI) Inspection Classification For Tampa Facility - PR Newswire (press release)
www.prnewswire.com - August 17 at 9:09 AM
investorplace.com logoThe Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak - Investorplace.com
investorplace.com - August 17 at 9:09 AM
finance.yahoo.com logoETFs with exposure to Valeant Pharmaceuticals International, Inc. : August 16, 2017
finance.yahoo.com - August 17 at 9:09 AM
finance.yahoo.com logoValeant Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - August 17 at 9:09 AM
finance.yahoo.com logoValeant’s Tampa manufacturing plant on track for a better bill of health
finance.yahoo.com - August 17 at 9:09 AM
americanbankingnews.com logoValeant Pharmaceuticals Intl Inc (VRX) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 16 at 3:10 PM
fool.ca logoLong-Term Investors: Buy the Dip With Valeant Pharmaceuticals Intl Inc. - The Motley Fool Canada
www.fool.ca - August 11 at 3:56 PM
seekingalpha.com logoValeant: Earnings Expose Problem - Seeking Alpha
seekingalpha.com - August 11 at 3:56 PM
americanbankingnews.com logoQ3 2017 Earnings Forecast for Valeant Pharmaceuticals Intl Inc Issued By Jefferies Group (TSE:VRX)
www.americanbankingnews.com - August 11 at 8:12 AM
finance.yahoo.com logoEdited Transcript of VRX.TO earnings conference call or presentation 8-Aug-17 12:00pm GMT
finance.yahoo.com - August 10 at 8:44 PM
fool.ca logoValeant Pharmaceutical Intl Inc. Is Back on the Growth Track: Time to Buy?
www.fool.ca - August 10 at 3:42 PM
seekingalpha.com logoValeant: There's No Denying It - Seeking Alpha
seekingalpha.com - August 10 at 3:42 PM
finance.yahoo.com logoValeant Pharmaceuticals International, Inc. :VRX-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 10 at 3:42 PM
nasdaq.com logoValeant (VRX) Beats Q2 Earnings, Sales in Line, Trims View - Nasdaq
www.nasdaq.com - August 10 at 9:31 AM
seekingalpha.com logoValeant: Much More Upside Remains, Despite Messy Quarter - Seeking Alpha
seekingalpha.com - August 10 at 9:31 AM
seekingalpha.com logoValeant Pharmaceuticals: A Lesson In Value Traps - Seeking Alpha
seekingalpha.com - August 10 at 9:31 AM
finance.yahoo.com logo5 Reasons Valeant's Situation Could Get Worse
finance.yahoo.com - August 10 at 9:31 AM

Social

Chart

Valeant Pharmaceuticals Intl (VRX) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff